Inogen (INGN) Q2 2026 earnings review
International Growth Masks Underlying Domestic Weakness
Inogen delivered a mixed Q2, achieving 3.0% YoY revenue growth and positive Adjusted EBITDA of $2.4M, prompting a raise in full-year profit guidance. However, beneath the surface, the turnaround story is heavily skewed. International sales surged 14.8%, acting as the sole growth engine. Conversely, the core U.S. market is struggling: U.S. sales fell 2.3% and the legacy rental business plunged 11.8%. Stripping out favorable foreign exchange rates, global constant-currency revenue growth was an anemic 0.6%. While management's cost discipline is successfully restoring profitability, the domestic top-line contraction remains a significant overhang.
🐂 Bull Case
Adjusted EBITDA was positive $2.4M, and full-year guidance was raised by 48% to $4.0M. Management is proving it can extract operating leverage even with sluggish top-line growth.
Overseas sales accelerated by 14.8% YoY, proving that Inogen's portable oxygen concentrators (POCs) continue to win market share in underpenetrated global markets.
🐻 Bear Case
The domestic business is reversing. U.S. sales fell 2.3% and rentals plummeted 11.8%. If the core domestic market cannot stabilize, international growth will eventually fail to offset the drag.
Reported growth of 3.0% looks passable, but constant-currency growth was just 0.6%. The company is heavily dependent on currency tailwinds to show top-line progress.
⚖️ Verdict: ⚪
Neutral. The operational discipline driving margin expansion is commendable, and the balance sheet is pristine. However, a growth company cannot sustainably rely on just one geographic segment while its domestic base shrinks.
Key Themes
International Expansion Sustains the Top Line
International sales grew an impressive 14.8% YoY to $41.3M, accelerating from recent quarters. This segment is effectively the sole driver of revenue growth, supported by the recent launch of the Rove 6 portable oxygen concentrator in Canada and continued penetration in European and emerging B2B markets.
Domestic Sales Growth Reversing
Management cites 'traction with U.S. distributors,' but the data directly contradicts this positive narrative. U.S. sales fell 2.3% YoY to $42.3M. This marks a concerning reversal for the core business and indicates that channel mix shifts and competitive pressures are severely limiting domestic expansion.
Gross Margin Expansion Despite Mix Shift
Adjusted gross margin improved by 65 basis points to 45.6%, up from 44.9% a year ago. This is a notable achievement given the structural shift away from high-margin direct-to-consumer rentals toward lower-margin B2B sales. Management successfully utilized cost-of-revenue improvements to expand margins.
Rental Business Decelerating Further
U.S. rentals fell 11.8% YoY to $11.6M, a steeper decline than the 8% drop seen in Q1. The structural market shift—where new oxygen therapy patients start with purchased POCs rather than ongoing rentals—is aggressively eroding this legacy high-margin segment.
Clinical Pipeline and Product Innovation
Inogen achieved Last Patient Last Visit (LPLV) for the Simeox H SCOPE Study in China, a critical milestone for accessing a massive new market, with data expected in H2 2026. Additionally, the publication of the QuOTE assessment tool for oxygen therapy provides clinical validation that can support broader adoption of their ecosystem.
Macro: Foreign Exchange Masking Underlying Weakness
The company's reported 3.0% revenue growth paints a resilient picture, but constant currency data reveals extreme vulnerability. Stripping out favorable FX, global revenue grew just 0.6% YoY. International growth drops from 14.8% to 8.3% on a constant currency basis. If the macro FX environment reverses, Inogen risks posting negative overall top-line growth.
Other KPIs
Reversing the recent trend of unprofitability. This is a 15.2% increase YoY and a strong recovery from the negative $1.4M posted in 26Q1, reflecting tighter cost controls and improved gross margins.
Strong cash generation in the quarter. With CapEx at $1.9M, Free Cash Flow was positive $1.0M. The balance sheet remains bulletproof with $106.8M in cash, zero debt, and capacity to execute on the recently utilized share repurchase program ($7.5M spent in H1).
Guidance
Stable. The midpoint implies ~3% YoY growth relative to FY25. This was updated from prior broader targets, locking in a modest growth expectation reliant on international execution to offset domestic weakness.
Accelerating. Raised significantly from previous expectations. This represents a 48.1% surge over the $2.7M reported in FY25, highlighting high confidence in operating leverage and cost discipline for the back half of the year.
Decelerating. Management expects Q3 to be 'approximately in line' with Q3 2025 ($92.4M). This implies 0% YoY growth, a step down from the 3.0% growth achieved in Q2, primarily due to timing impacts of international distributor inventory purchases.
Key Questions
Domestic Turnaround Timeline
U.S. sales declined 2.3% this quarter. With the addition of Andy Reding as COO, what specific tactical changes are being implemented to halt this contraction and return the domestic product business to growth?
FX Exposure and True Growth
Constant currency growth was only 0.6% this quarter. How much of the maintained FY26 revenue guidance ($355-$361M) is dependent on favorable foreign exchange rates continuing through the second half?
Simeox China Commercialization
With the Simeox H SCOPE Study in China reaching Last Patient Last Visit, what is the realistic regulatory timeline, and when do you expect this to become a material revenue contributor?